重度肾病患者采用高度限制碘对比剂方案行EVAR的规划、实施与随访
本研究描述了一种「近零对比剂」方案,用于肾功能严重受损(GFR<30 mL/min)的腹主动脉瘤患者行EVAR,通过非增强CT和超声规划、术中限制对比剂用量<20 mL,并采用CEUS随访。18例患者技术成功率100%,术后GFR无恶化≥30%,30天死亡率11%,随访期间无需透析。
要点
- 对GFR<30 mL/min的简单腹主动脉瘤解剖患者,近零对比剂EVAR可行。
- 术中平均碘对比剂用量18 mL,技术成功率100%,无肾功能恶化≥30%。
- 随访16个月无需透析,无再干预及动脉瘤相关死亡。
核心结论
- 对于简单主髂动脉解剖的重度肾功能不全患者,近零对比剂方案行EVAR可行且可避免肾功能损害。
研究设计与样本
- 回顾性研究,2012至2015年纳入18例高手术风险、适合标准EVAR且GFR<30 mL/min的腹主动脉瘤患者。
主要发现
- 中位年龄74岁,男性78%,ASA IV级100%,中位AAA直径66 mm,术前中位GFR 22 mL/min。
- 植入肾下型(n=10)和肾上固定型(n=8)支架,平均碘对比剂剂量18 mL,技术成功率100%。
- 术后中位GFR 22 mL/min,1天和30天无患者GFR恶化≥30%,30天死亡率11%(2例心力衰竭死亡)。
- 中位随访16个月,无患者需血液透析,未检测到内漏,无再干预及AAA或肾脏相关死亡。
关键数值与推荐
- 入选标准:高手术风险、适合标准EVAR的简单主髂解剖(近端和远端瘤颈长度≥15 mm,无严重成角),GFR<30 mL/min。
- 近零对比剂方案:术前非增强CT和双功能超声规划,术中碘对比剂用量<20 mL,随访采用双功能超声/CEUS。
临床怎么用
- 对于肾功能严重受损的简单解剖AAA患者,可考虑采用近零对比剂方案行EVAR以减少对比剂肾病风险。
局限性
- 样本量小(18例),非随机对照,随访时间较短,仅适用于简单主髂解剖患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The cumulative amount of iodinated contrast medium necessary for endovascular repair (EVAR) planning, operative procedure, and subsequent follow-up is a threat for the onset of end-stage renal disease in patients with preoperative impaired kidney function. The purpose of this study was to describe a mini-invasive approach aimed to minimize the exposure of these patients to iodinated contrast medium and the subsequent risk of renal function worsening. METHODS: From 2012 to 2015, all patients with abdominal aortic aneurysm (AAA) at high surgical risk and fit for standard EVAR (simple aortic-iliac anatomy: proximal and distal neck length ≥15 mm, no severe angulation), underwent EVAR through the following "near-zero contrast" approach, if their glomerular filtration rate (GFR) was <30 mL/min: preoperative planning was performed by noncontrast-enhanced computed tomography and duplex ultrasound (DU); the origin of renal/hypogastric arteries and aortic bifurcation was evaluated and matched with vertebral bone landmarks and the endograft deployed accordingly, using <20 cc of isotonic iodinate contrast medium and contrast-enhancement DU (CEUS). Follow-up was by DU/CEUS at 1, 6, and 12 months. Primary end points were technical success (TS: renal/hypogastric artery patency, absence of type I/III endoleaks, iliac stenosis/kinking, intraoperative mortality, and conversion), 30-day mortality, and new onset of permanent dialysis with renal function evaluation at 1, 6, and 12 months. Secondary end points were type II endoleaks, reinterventions, AAA, and renal-related mortality during the follow-up. RESULTS: Eighteen patients (median age: 74 years, interquartile range [IQR]: 6, male: 78%, American Society of Anaesthesiologists [ASA] IV: 100%) were enrolled. The median AAA diameter and preoperative GFR were 66 mm (IQR: 13) and 22 mL/min (IQR: 4), respectively. Infrarenal (n = 10) and suprarenal fixation (n = 8) endografts were implanted, with a mean dose of iodinate contrast medium injection of 18 mL (IQR) and 100% TS rate. Two type II endoleaks were detected at the completion CEUS. The median postoperative GFR was 22 mL/min (IQR: 5). No patients had GFR worsening ≥30% at 1 day and 30 days. The 30-day mortality was 11% (2 deaths for heart failure). At a median follow-up of 16 months (IQR: 8), no patients needed hemodialytic treatment and no endoleaks were detected. One patient died at 6 months for cancer and one at 13 months for myocardial infarction. No reinterventions or AAA and renal-related mortality occurred during the follow-up. CONCLUSIONS: A "near-zero contrast" approach is feasible in EVAR for patients with simple aorto-iliac anatomy. Patients with very poor renal function may still undergo to successful procedures, avoiding renal function impairment.
引用
- Gallitto E, Faggioli G, Gargiulo M, et al. Planning, Execution, and Follow-up for Endovascular Aortic Aneurysm Repair Using a Highly Restrictive Iodinated Contrast Protocol in Patients with Severe Renal Disease. Ann Vasc Surg. 2017. PMID: 28648650. doi:10.1016/j.avsg.2017.06.050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。